Mobloc (Metoprolol Succinate, Felodipine)

Metoprolol succinate / felodipine, the active ingredient in Mobloc, is a beta‑blocker and calcium‑channel blocker combination presented as a tablet for oral use. It works to reduce high blood pressure by decreasing heart rate and dilating arteries, providing therapeutic benefit for adult patients diagnosed with hypertension.

GNH USA supplies Mobloc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality manufacturing standards and reliable global distribution for healthcare providers seeking consistent access to this antihypertensive medication.

Mobloc, a combined beta‑blocker and calcium‑channel blocker, is indicated for the management of hypertension.

- Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Secondary hypertension (e.g., renal‑related): assists in achieving blood pressure control when monotherapy is insufficient. - High cardiovascular risk patients with hypertension: provides combined heart‑rate reduction and arterial vasodilation to lower overall cardiovascular strain.

Like all antihypertensive agents, Mobloc may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache may occur. - Dizziness or light‑headedness: especially upon standing. - Peripheral edema: swelling of ankles or feet. - Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects: - Bradycardia: abnormally slow heart rate requiring medical attention. - Hypotension: excessive drop in blood pressure leading to fainting. - Heart block: conduction disturbances that may necessitate discontinuation.

Prior to prescribing Mobloc, clinicians should evaluate patient history and monitor specific parameters to ensure safe use.

- Assess cardiac function: evaluate for existing heart failure or conduction abnormalities. - Monitor blood pressure: check for excessive hypotension after initiation or dose changes. - Check renal and hepatic function: adjust therapy if significant impairment is present. - Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. - Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture.

Mobloc can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase felodipine levels, risking hypotension. - Non‑selective beta‑blockers or other antihypertensives: additive blood pressure lowering effect leading to severe hypotension. - Calcium‑channel blocker antagonists (e.g., diltiazem, verapamil): can raise metoprolol concentrations, increasing bradycardia risk.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring. - Antidiabetic agents: beta‑blockade may mask hypoglycemia symptoms, necessitating glucose monitoring.